Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Combined with Apatinib and Chemotherapy for Unresectable Biliary Tract Cancer
NCT07135544Phase 2Recruiting
- Start
- Aug 2025
- Primary completion
- Jun 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in biliary tract cancer (BTC). Started Aug 2025; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07135544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07135544.